ROVI has commenced the marketing of its enoxaparin biosimilar in Spain


No votes yet
 
Related
  ROVI takes first place in the Sustainalytics world ESG risk ranking for the second year running Laboratorios Farmacéuticos...
3 min
04/08/2023
ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® The United States Food and Drug Administration (...
1 min
28/07/2023
ROVI ACHIEVED STABLE TOTAL REVENUE OF 381.0 MILLION EUROS IN THE FIRST POST-PANDEMIC HALF YEAR Operating revenue remained stable,...
4 min
26/07/2023